Events and Networking

Expand Your Network at One of Biocom’s 150+ Annual Events

How is the FDA Approaching Regulation under the Trump Administration?

When:

Wed Feb 14 19:30:00 GMT 2018 - Wed Feb 14 21:30:00 GMT 2018

Where:

CBRE
234 S Brand Blvd #800
Glendale, 91204

Register

The Food and Drug Administration’s approach to regulating emerging technologies has been evolving rapidly, including with regard to precision therapeutics, novel diagnostics, digital health technologies, and regenerative medicine, to name a few areas of medical innovation. Learn how new FDA authorities and policies may affect your regulatory pathway -- and help save development time and costs down the road. Join leading FDA regulatory lawyers, Wade Ackerman and Scott Cunningham from Covington, for this insightful and informative program. Covington is one of the largest and most comprehensive life sciences practices across the globe, and Wade and Scott are resident in Covington’s LA and SF offices.


Speakers: 
Wade Ackerman, Partner, Convington & Burling LLP 

Wade Ackerman is a leading FDA regulatory lawyer based in Covington’s Los Angeles office. With a combination of substantive life sciences expertise, a high profile in the industry, and significant federal government experience, Mr. Ackerman has a unique practice for the Southern California legal market. After starting his legal career in Los Angeles, Mr. Ackerman spent eight years in the federal government in Washington, DC, and returned to Los Angeles in 2016 to join Covington as a partner. Mr. Ackerman helps companies navigate FDA regulatory and policy issues, leveraging his experience both at the FDA and on the Hill. Until June 2016, Mr. Ackerman served as Senior FDA Counsel to the U.S. Senate Health, Education, Labor & Pensions (HELP) Committee. Before taking his role in the Senate, Mr. Ackerman served for five years within the Administration as Associate Chief Counsel in FDA’s Office of the Chief Counsel.

Scott Cunningham, Partner, Convington & Burling LLP 
Scott Cunningham is a partner in Covington’s Food, Drug and Device practice group, based in
San Francisco. He represents pharmaceutical, biotechnology, regenerative medicine, and medical device companies as well as trade associations in matters before the FDA, Congress, state and federal courts, and other regulatory and enforcement agencies. Mr. Cunningham has significant experience in the full range of FDA-related issues from preclinical and clinical development, to approval pathways, to post-approval matters. He also has extensive experience in health care compliance and fraud/abuse matters.

Sponsored By: 

User-added image
User-added image




 

Price of Admission

Biocom Non-member

Today's Price: 25.0

Important Dates

Amount

Registration Before

Registration Before

Registration Before

Refund after Thu Feb 15 00:00:00 GMT 2018

0.0

Refund after

Refund after

Biocom Member

Today's Price: 15.0

Important Dates

Amount

Registration Before

Registration Before

Registration Before

Refund after Thu Feb 15 00:00:00 GMT 2018

0.0

Refund after

Refund after

 

Register